Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021

Descripción del Articulo

Background: During 2021, Peru started the vaccination against SARS-CoV-2 using the BBIBP-CorV inactivated virus vaccine for health care workers (HCW). We aim to evaluate the effectiveness of the BBIBP-CorV vaccine to prevent SARS-CoV-2 infection and deaths among HCWs. Methods: Retrospective cohort s...

Descripción completa

Detalles Bibliográficos
Autores: Silva-Valencia, Javier, Soto-Becerra, Percy, Escobar Agreda, Stefan, Fernández Navarro, Manuel, Moscoso Porras, Miguel, Solari, Lely, Mayta Tristán, Percy
Formato: artículo
Fecha de Publicación:2023
Institución:Seguro Social de Salud
Repositorio:ESSALUD-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.essalud.gob.pe:20.500.12959/3472
Enlace del recurso:https://hdl.handle.net/20.500.12959/3472
https://doi.org/10.1016/j.tmaid.2023.102565
Nivel de acceso:acceso abierto
Materia:Effectiveness
Health care workers
BBIBP-CorV
Covid-19
Infecciones por coronavirus
Perú
https://purl.org/pe-repo/ocde/ford#3.03.08
https://purl.org/pe-repo/ocde/ford#3.03.09
id ESSA_e89854b15c8c6dc5d460dd3b89c53097
oai_identifier_str oai:repositorio.essalud.gob.pe:20.500.12959/3472
network_acronym_str ESSA
network_name_str ESSALUD-Institucional
repository_id_str 4277
dc.title.es_PE.fl_str_mv Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
dc.title.alternative.es_PE.fl_str_mv Efectividad de la vacuna BBIBP-CorV en la prevención de infección y muerte en trabajadores de la salud en Perú 2021
title Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
spellingShingle Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
Silva-Valencia, Javier
Effectiveness
Health care workers
BBIBP-CorV
Covid-19
Infecciones por coronavirus
Perú
https://purl.org/pe-repo/ocde/ford#3.03.08
https://purl.org/pe-repo/ocde/ford#3.03.09
title_short Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
title_full Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
title_fullStr Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
title_full_unstemmed Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
title_sort Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021
author Silva-Valencia, Javier
author_facet Silva-Valencia, Javier
Soto-Becerra, Percy
Escobar Agreda, Stefan
Fernández Navarro, Manuel
Moscoso Porras, Miguel
Solari, Lely
Mayta Tristán, Percy
author_role author
author2 Soto-Becerra, Percy
Escobar Agreda, Stefan
Fernández Navarro, Manuel
Moscoso Porras, Miguel
Solari, Lely
Mayta Tristán, Percy
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva-Valencia, Javier
Soto-Becerra, Percy
Escobar Agreda, Stefan
Fernández Navarro, Manuel
Moscoso Porras, Miguel
Solari, Lely
Mayta Tristán, Percy
dc.subject.es_PE.fl_str_mv Effectiveness
Health care workers
BBIBP-CorV
Covid-19
Infecciones por coronavirus
Perú
topic Effectiveness
Health care workers
BBIBP-CorV
Covid-19
Infecciones por coronavirus
Perú
https://purl.org/pe-repo/ocde/ford#3.03.08
https://purl.org/pe-repo/ocde/ford#3.03.09
dc.subject.ocde.es_PE.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.03.08
https://purl.org/pe-repo/ocde/ford#3.03.09
description Background: During 2021, Peru started the vaccination against SARS-CoV-2 using the BBIBP-CorV inactivated virus vaccine for health care workers (HCW). We aim to evaluate the effectiveness of the BBIBP-CorV vaccine to prevent SARS-CoV-2 infection and deaths among HCWs. Methods: Retrospective cohort study, from February 9 to June 30, 2021, using national registries of health care workers, laboratory tests for SARS-CoV-2 and deaths. We calculated the vaccine effectiveness for preventing laboratory-confirmed SARS-CoV-2 infection, COVID-19-mortality, and all-cause mortality among partially immunized and fully immunized HCWs. An extension of Cox proportional hazards regression was used to model the mortality results, and Poisson regression was used to model SARS-CoV-2 infection. Results: The study included 606,772 eligible HCWs, the mean age was 40 (IQR: 33.0, 51.0). In fully immunized HCW, the effectiveness for preventing all-cause mortality was 83.6 (95% CI: 80.2 to 86.4), 88.7 (95% CI: 85.1 to 91.4) for preventing COVID-19 mortality, and 40.3 (95% CI 38.9 to 41.6) for preventing SARS-CoV-2 infection. Conclusion: The BBIBP-CorV vaccine showed high levels of effectiveness for preventing all-cause and COVID-19 deaths among fully immunized HCW. These results were consistent within different subgroups and sensitivity analyses. However, the effectiveness for preventing infection was suboptimal in this particular setting.
publishDate 2023
dc.date.accessioned.none.fl_str_mv 2023-03-17T18:11:46Z
dc.date.available.none.fl_str_mv 2023-03-17T18:11:46Z
dc.date.issued.fl_str_mv 2023-03-16
dc.type.es_PE.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.citation.es_PE.fl_str_mv Travel Medicine and Infectious Disease. 2023
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12959/3472
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.tmaid.2023.102565
identifier_str_mv Travel Medicine and Infectious Disease. 2023
url https://hdl.handle.net/20.500.12959/3472
https://doi.org/10.1016/j.tmaid.2023.102565
dc.language.iso.es_PE.fl_str_mv eng
language eng
dc.relation.uri.es_PE.fl_str_mv https://www.sciencedirect.com/science/article/pii/S147789392300025X?via%3Dihub
dc.rights.es_PE.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.es_PE.fl_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.es_PE.fl_str_mv application/pdf
dc.publisher.es_PE.fl_str_mv Royal College of Physicians and Surgeons de Glasgow
dc.source.none.fl_str_mv reponame:ESSALUD-Institucional
instname:Seguro Social de Salud
instacron:ESSALUD
instname_str Seguro Social de Salud
instacron_str ESSALUD
institution ESSALUD
reponame_str ESSALUD-Institucional
collection ESSALUD-Institucional
bitstream.url.fl_str_mv https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/1/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdf
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/2/license.txt
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/3/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdf.txt
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/4/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdf.jpg
bitstream.checksum.fl_str_mv e10ded056ba9a393f621f4f582e3dbd6
8a4605be74aa9ea9d79846c1fba20a33
6cae03fd417e037de4c69bcdf8a533da
98800c9164ab41f482c4a6348ec2f6b8
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Seguro Social de Salud – ESSALUD
repository.mail.fl_str_mv bibliotecacentral@essalud.gob.pe
_version_ 1813537148405547008
spelling Silva-Valencia, JavierSoto-Becerra, PercyEscobar Agreda, StefanFernández Navarro, ManuelMoscoso Porras, MiguelSolari, LelyMayta Tristán, Percy2023-03-17T18:11:46Z2023-03-17T18:11:46Z2023-03-16Travel Medicine and Infectious Disease. 2023https://hdl.handle.net/20.500.12959/3472https://doi.org/10.1016/j.tmaid.2023.102565Background: During 2021, Peru started the vaccination against SARS-CoV-2 using the BBIBP-CorV inactivated virus vaccine for health care workers (HCW). We aim to evaluate the effectiveness of the BBIBP-CorV vaccine to prevent SARS-CoV-2 infection and deaths among HCWs. Methods: Retrospective cohort study, from February 9 to June 30, 2021, using national registries of health care workers, laboratory tests for SARS-CoV-2 and deaths. We calculated the vaccine effectiveness for preventing laboratory-confirmed SARS-CoV-2 infection, COVID-19-mortality, and all-cause mortality among partially immunized and fully immunized HCWs. An extension of Cox proportional hazards regression was used to model the mortality results, and Poisson regression was used to model SARS-CoV-2 infection. Results: The study included 606,772 eligible HCWs, the mean age was 40 (IQR: 33.0, 51.0). In fully immunized HCW, the effectiveness for preventing all-cause mortality was 83.6 (95% CI: 80.2 to 86.4), 88.7 (95% CI: 85.1 to 91.4) for preventing COVID-19 mortality, and 40.3 (95% CI 38.9 to 41.6) for preventing SARS-CoV-2 infection. Conclusion: The BBIBP-CorV vaccine showed high levels of effectiveness for preventing all-cause and COVID-19 deaths among fully immunized HCW. These results were consistent within different subgroups and sensitivity analyses. However, the effectiveness for preventing infection was suboptimal in this particular setting.Antescedentes: Durante 2021, Perú inició la vacunación contra el SARS-CoV-2 utilizando la vacuna de virus inactivado BBIBP-CorV para trabajadores de la salud (TS). Nuestro objetivo es evaluar la eficacia de la vacuna BBIBP-CorV para prevenir la infección por SARS-CoV-2 y las muertes entre los trabajadores sanitarios. Métodos: Estudio de cohorte retrospectivo, del 9 de febrero al 30 de junio de 2021, utilizando registros nacionales de trabajadores de la salud, pruebas de laboratorio para SARS-CoV-2 y defunciones. Calculamos la efectividad de la vacuna para prevenir la infección por SARS-CoV-2 confirmada por laboratorio, la mortalidad por COVID-19 y la mortalidad por todas las causas entre los trabajadores de la salud parcialmente inmunizados y totalmente inmunizados. Se usó una extensión de la regresión de riesgos proporcionales de Cox para modelar los resultados de mortalidad, y se usó la regresión de Poisson para modelar la infección por SARS-CoV-2. Resultados: El estudio incluyó a 606 772 HCW elegibles, la edad media fue de 40 años (IQR: 33,0, 51,0). En trabajadores de la salud totalmente inmunizados, la eficacia para prevenir la mortalidad por todas las causas fue de 83,6 (IC del 95 %: 80,2 a 86,4), 88,7 (IC del 95 %: 85,1 a 91,4) para prevenir la mortalidad por COVID-19 y 40,3 (IC del 95 %: 38,9 a 91,4). 41.6) para prevenir la infección por SARS-CoV-2. Conclusión: La vacuna BBIBP-CorV mostró altos niveles de efectividad para prevenir muertes por todas las causas y por COVID-19 entre trabajadores de la salud completamente inmunizados. Estos resultados fueron consistentes dentro de diferentes subgrupos y análisis de sensibilidad. Sin embargo, la efectividad para prevenir infecciones fue subóptima en este entorno particular.application/pdfengRoyal College of Physicians and Surgeons de Glasgowhttps://www.sciencedirect.com/science/article/pii/S147789392300025X?via%3Dihubinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/EffectivenessHealth care workersBBIBP-CorVCovid-19Infecciones por coronavirusPerúhttps://purl.org/pe-repo/ocde/ford#3.03.08https://purl.org/pe-repo/ocde/ford#3.03.09Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021Efectividad de la vacuna BBIBP-CorV en la prevención de infección y muerte en trabajadores de la salud en Perú 2021info:eu-repo/semantics/articlereponame:ESSALUD-Institucionalinstname:Seguro Social de Saludinstacron:ESSALUDORIGINALEffectiveness of the BBIBP-CorV vaccine.pdfEffectiveness of the BBIBP-CorV vaccine.pdfapplication/pdf1462433https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/1/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdfe10ded056ba9a393f621f4f582e3dbd6MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTEffectiveness of the BBIBP-CorV vaccine.pdf.txtEffectiveness of the BBIBP-CorV vaccine.pdf.txtExtracted texttext/plain46921https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/3/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdf.txt6cae03fd417e037de4c69bcdf8a533daMD53THUMBNAILEffectiveness of the BBIBP-CorV vaccine.pdf.jpgEffectiveness of the BBIBP-CorV vaccine.pdf.jpgGenerated Thumbnailimage/jpeg4805https://repositorio.essalud.gob.pe/bitstream/20.500.12959/3472/4/Effectiveness%20of%20the%20BBIBP-CorV%20vaccine.pdf.jpg98800c9164ab41f482c4a6348ec2f6b8MD5420.500.12959/3472oai:repositorio.essalud.gob.pe:20.500.12959/34722023-03-18 03:00:26.649Repositorio Seguro Social de Salud – ESSALUDbibliotecacentral@essalud.gob.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
score 13.909792
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).